For example, in CML, NGS can detect compound mutations in the BCR::ABL1 kinase domain that contribute to TKI resistance, whereas Sanger sequencing often fails to distinguish between polyclonal and compound mutations [100,101]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.